Ionis Pharmaceuticals Valuation
| IONS Stock | USD 81.36 0.76 0.94% |
At this time, the firm appears to be undervalued. Ionis Pharmaceuticals retains a regular Real Value of $88.74 per share. The prevalent price of the firm is $81.36. Our model calculates the value of Ionis Pharmaceuticals from evaluating the firm fundamentals such as Return On Equity of -0.4, return on asset of -0.0568, and Current Valuation of 12.3 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ionis Pharmaceuticals' valuation include:
Price Book 21.1259 | Enterprise Value | Enterprise Value Ebitda (22.08) | Price Sales 13.5013 | Forward PE 90.9091 |
Undervalued
Today
Please note that Ionis Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Ionis Pharmaceuticals is based on 3 months time horizon. Increasing Ionis Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ionis stock is determined by what a typical buyer is willing to pay for full or partial control of Ionis Pharmaceuticals. Since Ionis Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ionis Stock. However, Ionis Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 81.36 | Real 88.74 | Target 91.13 | Hype 81.83 |
The intrinsic value of Ionis Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ionis Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ionis Pharmaceuticals helps investors to forecast how Ionis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ionis Pharmaceuticals more accurately as focusing exclusively on Ionis Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ionis Pharmaceuticals' intrinsic value based on its ongoing forecasts of Ionis Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ionis Pharmaceuticals' closest peers.
Ionis Pharmaceuticals Cash |
|
Ionis Revenue by Product
Ionis Pharmaceuticals Total Value Analysis
Ionis Pharmaceuticals is currently estimated to have valuation of 12.3 B with market capitalization of 13.06 B, debt of 1.42 B, and cash on hands of 2.04 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ionis Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.3 B | 13.06 B | 1.42 B | 2.04 B |
Ionis Pharmaceuticals Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 101.16. Ionis Pharmaceuticals recorded a loss per share of 1.61. The entity had not issued any dividends in recent years. Based on the key indicators related to Ionis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Ionis Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Ionis Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ionis Pharmaceuticals has an asset utilization ratio of 23.48 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Ionis Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Ionis Pharmaceuticals Profitability Analysis
Based on Ionis Pharmaceuticals' profitability indicators, Ionis Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Ionis Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 1990-03-31 | Previous Quarter 123.6 M | Current Value -128.6 M | Quarterly Volatility 63.2 M |
For Ionis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ionis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ionis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ionis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ionis Pharmaceuticals over time as well as its relative position and ranking within its peers.
Ionis Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing Ionis Pharmaceuticals' earnings estimates, investors can diagnose different trends across Ionis Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Ionis Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Ionis Pharmaceuticals Ownership Allocation
Ionis Pharmaceuticals has a total of 161.97 Million outstanding shares. The majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ionis Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 705.14 M. Net Loss for the year was (453.9 M) with profit before overhead, payroll, taxes, and interest of 73.71 M.About Ionis Pharmaceuticals Valuation
The stock valuation mechanism determines Ionis Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Ionis Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ionis Pharmaceuticals. We calculate exposure to Ionis Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ionis Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 798 M | 837.9 M | |
| Pretax Profit Margin | (0.59) | (0.56) | |
| Operating Profit Margin | (0.61) | (0.64) | |
| Net Loss | (0.58) | (0.61) | |
| Gross Profit Margin | 0.89 | 0.45 |
Ionis Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ionis Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 149.5 M | |
| Quarterly Earnings Growth Y O Y | -0.437 | |
| Forward Price Earnings | 90.9091 |
Ionis Pharmaceuticals Current Valuation Indicators
Ionis Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Ionis Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ionis Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ionis Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ionis Pharmaceuticals' worth.Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.